SEC Form 4 · accession 0001562180-17-002530
Avalo Therapeutics, Inc. · AVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eugene A Bauer
Director
Period of report
Jun 30, 2017
Accepted (ET)
Jul 31, 2017 · 1:34 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534120
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $0.57 | Jun 30, 2017 | A | 8,357 | A | Jun 30, 2018 | Jun 29, 2027 | Common Stock | 8,357 | 8,357 | D |
Explanation of responses
- F1The stock options will vest in full on June 30, 2018, subject to the grantees continued service on such vesting date.